Kabingu E, Vaughan L, Owczarczak B, Ramsey K D, Gollnick S O
Department of Cell Stress Biology, PDT Center, Roswell Park Cancer Center, Elm and Carlton Sts., Buffalo, NY 14263, USA.
Br J Cancer. 2007 Jun 18;96(12):1839-48. doi: 10.1038/sj.bjc.6603792. Epub 2007 May 15.
Cancer survival rates decrease in the presence of disseminated disease. However, there are few therapies that are effective at eliminating the primary tumour while providing control of distant stage disease. Photodynamic therapy (PDT) is an FDA-approved modality that rapidly eliminates local tumours, resulting in cure of early disease and palliation of advanced disease. Numerous pre-clinical studies have shown that local PDT treatment of tumours enhances anti-tumour immunity. We hypothesised that enhancement of a systemic anti-tumour immune response might control the growth of tumours present outside the treatment field. To test this hypothesis we delivered PDT to subcutaneous (s.c.) tumours of mice bearing both s.c. and lung tumours and monitored the growth of the untreated lung tumours. Our results demonstrate that PDT of murine tumours provided durable inhibition of the growth of untreated lung tumours. The inhibition of the growth of tumours outside the treatment field was tumour-specific and dependent on the presence of CD8(+) T cells. This inhibition was accompanied by an increase in splenic anti-tumour cytolytic activity and by an increase in CD8(+) T cell infiltration into untreated tumours. Local PDT treatment led to enhanced anti-tumour immune memory that was evident 40 days after tumour treatment and was independent of CD4(+) T cells. CD8(+) T cell control of the growth of lung tumours present outside the treatment field following PDT was dependent upon the presence of natural killer (NK) cells. These results suggest that local PDT treatment of tumours lead to induction of an anti-tumour immune response capable of controlling the growth of tumours outside the treatment field and indicate that this modality has potential in the treatment of distant stage disease.
在存在播散性疾病的情况下,癌症生存率会降低。然而,在消除原发性肿瘤同时控制远处疾病阶段的有效疗法却很少。光动力疗法(PDT)是一种经美国食品药品监督管理局(FDA)批准的治疗方式,可迅速消除局部肿瘤,从而治愈早期疾病并缓解晚期疾病。大量临床前研究表明,对肿瘤进行局部光动力疗法治疗可增强抗肿瘤免疫力。我们推测,增强全身抗肿瘤免疫反应可能会控制治疗区域外肿瘤的生长。为了验证这一假设,我们对同时患有皮下和肺部肿瘤的小鼠的皮下肿瘤进行了光动力疗法治疗,并监测未治疗的肺部肿瘤的生长情况。我们的结果表明,对小鼠肿瘤进行光动力疗法可持久抑制未治疗的肺部肿瘤的生长。对治疗区域外肿瘤生长的抑制具有肿瘤特异性,且依赖于CD8(+) T细胞的存在。这种抑制伴随着脾脏抗肿瘤细胞溶解活性的增加以及CD8(+) T细胞向未治疗肿瘤的浸润增加。局部光动力疗法治疗导致抗肿瘤免疫记忆增强,这在肿瘤治疗后40天很明显,且与CD4(+) T细胞无关。光动力疗法后,CD8(+) T细胞对治疗区域外肺部肿瘤生长的控制依赖于自然杀伤(NK)细胞的存在。这些结果表明,对肿瘤进行局部光动力疗法治疗可诱导产生一种能够控制治疗区域外肿瘤生长的抗肿瘤免疫反应,并表明这种治疗方式在治疗远处疾病阶段具有潜力。